Century Therapeutics (IPSC) Current Deferred Revenue (2022 - 2024)
Century Therapeutics (IPSC) posted quarterly Current Deferred Revenue of $109.2 million for Q4 2024, up 2396.89% year-over-year from $4.4 million in Q1 2024, and up 2958.67% quarter-over-quarter from $3.6 million in Q3 2024.
Century Therapeutics (IPSC) Current Deferred Revenue (2022 - 2024) Analysis & Trends
Century Therapeutics (IPSC) has reported Current Deferred Revenue for 3 consecutive years, with $109.2 million the latest figure, recorded in Q4 2024.
- In Q4 2024, Current Deferred Revenue rose 2396.89% year-over-year to $109.2 million; the TTM figure through Dec 2024 stood at $109.2 million (up 2396.89% YoY), while the FY2024 annual figure was $109.2 million, up 2396.89% from the prior year.
- Current Deferred Revenue climbed to $109.2 million in Q4 2024 per IPSC's latest filing, from $3.6 million in the prior quarter.
- Across five years, Current Deferred Revenue topped out at $109.2 million in Q4 2024 and bottomed at $3.6 million in Q3 2024.
- Historically, Current Deferred Revenue has averaged $14.4 million across 3 years, with a median of $6.4 million in 2022.
- Annual changes were most pronounced in 2023 — Current Deferred Revenue plunged 48.87% — and 2024, when it surged 2396.89%.
- Century Therapeutics' Current Deferred Revenue stood at $7.2 million in 2022, then plunged by 38.89% to $4.4 million in 2023, then soared by 2396.89% to $109.2 million in 2024.
- Business Quant data shows IPSC's Current Deferred Revenue at $109.2 million in Q4 2024, $3.6 million in Q3 2024, and $4.4 million in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Century Therapeutics | 346.65 Mn | 86.58 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 109.16 Mn |
| Sep 30, 2024 | 3.57 Mn |
| Jun 30, 2024 | 4.36 Mn |
| Mar 31, 2024 | 4.61 Mn |
| Dec 31, 2023 | 4.37 Mn |
| Sep 30, 2023 | 3.87 Mn |
| Jun 30, 2023 | 6.94 Mn |
| Mar 31, 2023 | 6.50 Mn |
| Dec 31, 2022 | 7.15 Mn |
| Sep 30, 2022 | 7.57 Mn |
| Jun 30, 2022 | 7.82 Mn |
| Mar 31, 2022 | 6.38 Mn |